Two new directors to join the Danish Medicines Agency
The Danish Medicines Agency has appointed Janne Lehmann Knudsen as Director of Pharmacovigilance & Medical Devices and Iben Vitved as Director of Finance.
Janne Lehmann Knudsen was previously quality manager in the Quality & Patient Safety department of the Danish Cancer Society where she worked to improve coherence in cancer pathways in a professional and organisational perspective and with focus on patients. She is currently chairman of the Advisory Board of the Danish Knowledge Center for User Involvement in Health Care (ViBIS). She has a background as a medical specialist and holds a Ph.D.
”The vast majority of those who are struck by disease receive medical treatment or come in contact with medical devices. Patient safety must be of a high quality, and I want to strengthen this field. I am looking forward to heading this important area, which is decisive for offering patients the best possible treatment,” says Janne Lehmann Knudsen.
Iben Vitved comes from a position as chief financial officer of the Danish Security and Intelligence Service (PET). She has an MSc in economics and was formerly chief accountant of the Danish Health Authority.
”I look forward to joining the leadership team of an independent agency with competent and dedicated employees. Together we will realise the Danish government's high ambitions of shorter assessment times and more advice to companies. Most of all to protect patient safety, but also to contribute to growth in Denmark,” says Iben Vitved.
Both Janne Lehmann Knudsen and Iben Vitved will join the Danish Medicines Agency on 1 June.
Director General Thomas Senderovitz is very satisfied with the appointments. ”It is a great advantage that two highly qualified persons now join the Danish Medicines Agency’s Leadership Team. I am looking forward to welcoming them to join our organisation and professional profile,” he says.
